Langabeer S, Haslam K, Crampe M, MacDonagh B, McHugh J. Suboptimal molecular response to tyrosine kinase inhibition associated with acquisition of a T240A ABL1 kinase domain mutation in a patient with chronic myeloid leukemia. Exp. oncol. [Internet]. 2023 Jun. 8 [cited 2025 May 19];41(1):82-3. Available from: https://exp-oncology.com.ua/index.php/Exp/article/view/2019-1-1